Capricor shares rise after new data on deramiocel presented at muscle society congress
Capricor Therapeutics (CAPR) saw a surge in its stock price during late trading Tuesday following the release of updated clinical data for its experimental drug, deramiocel. The information was shared as part of the 31st Annual Congress of the World Muscle Society and highlighted longer-term effects observed from the treatment. Deramiocel is being developed to treat Duchenne muscular dystrophy (DMD), a severe genetic disorder affecting muscle development in children. Positive results showing sustained benefits could increase investor confidence, especially given the limited therapeutic options currently available for DMD patients.
Tickers: $CAPR
Topics: biotech clinical trials deramiocel Duchenne muscular dystrophy